0 19 Posttranscriptional posttranscriptional JJ 20 30 regulation regulation NN 31 33 of of IN 34 44 macrophage macrophage NN 45 51 tissue tissue NN 52 58 factor factor NN 59 69 expression expression NN 70 72 by by IN 73 85 antioxidants antioxidant NNS 85 86 . . . 88 94 Tissue tissue NN 95 101 factor factor NN 102 103 ( ( ( 103 105 TF TF NNP 105 106 ) ) ) 107 117 expression expression NN 118 120 by by IN 121 126 cells cell NNS 127 129 of of IN 130 149 monocyte/macrophage monocyte/macrophage NN 150 157 lineage lineage NN 158 168 represents represent VBZ 169 171 an an DT 172 181 important important JJ 182 191 mechanism mechanism NN 192 202 underlying underlie VBG 203 206 the the DT 207 217 initiation initiation NN 218 220 of of IN 221 227 fibrin fibrin NN 228 238 deposition deposition NN 239 241 at at IN 242 247 sites site NNS 248 250 of of IN 251 264 extravascular extravascular JJ 265 277 inflammation inflammation NN 277 278 . . . 279 285 Recent recent JJ 286 294 evidence evidence NN 295 303 suggests suggest VBZ 304 305 a a DT 306 310 role role NN 311 314 for for IN 315 322 oxidant oxidant JJ 323 329 stress stress NN 330 332 in in IN 333 336 the the DT 337 347 signalling signalling NN 348 355 pathway pathway NN 356 358 of of IN 359 366 various various JJ 367 371 cell cell NN 372 377 types type NNS 378 380 by by IN 381 387 virtue virtue NN 388 390 of of IN 391 394 its its PRP$ 395 402 ability ability NN 403 405 to to TO 406 412 induce induce VB 413 416 DNA dna NN 417 424 binding binding NN 425 427 of of IN 428 435 various various JJ 436 449 transcription transcription NN 450 457 factors factor NNS 457 458 , , , 459 468 including include VBG 469 476 nuclear nuclear JJ 477 483 factor factor NN 484 489 kappa kappa NN 490 491 B B NNP 492 495 and and CC 496 500 AP-1 ap-1 NN 500 501 . . . 502 505 The the DT 506 512 effect effect NN 513 515 of of IN 516 527 antioxidant antioxidant JJ 528 537 treatment treatment NN 538 540 on on IN 541 559 lipopolysaccharide lipopolysaccharide NN 560 561 ( ( ( 561 573 LPS)-induced lps)-induced JJ 574 576 TF TF NNP 577 587 expression expression NN 588 591 was be VBD 592 600 examined examine VBN 601 603 in in IN 604 610 murine murine JJ 611 621 peritoneal peritoneal JJ 622 633 macrophages macrophage NNS 634 637 and and CC 638 643 human human JJ 644 653 monocytes monocyte NNS 653 654 . . . 655 659 Both both CC 660 671 pyrrolidine pyrrolidine NN 672 687 dithiocarbamate dithiocarbamate NN 687 688 , , , 689 691 an an DT 692 699 oxidant oxidant JJ 700 709 scavenger scavenger NN 709 710 , , , 711 714 and and CC 715 732 N-acetyl-cysteine N-acetyl-cysteine NNP 732 733 , , , 734 735 a a DT 736 745 precursor precursor NN 746 748 of of IN 749 752 the the DT 753 763 endogenous endogenous JJ 764 775 antioxidant antioxidant JJ 776 787 glutathione glutathione NN 787 788 , , , 789 798 inhibited inhibit VBD 799 810 stimulation stimulation NN 811 813 of of IN 814 824 macrophage macrophage NN 825 837 procoagulant procoagulant NN 838 846 activity activity NN 847 849 by by IN 850 853 LPS LPS NNP 853 854 . . . 855 863 Northern Northern NNP 864 868 blot blot NN 869 877 analysis analysis NN 878 884 showed show VBD 885 889 that that IN 890 897 neither neither DT 898 900 of of IN 901 906 these these DT 907 913 agents agent NNS 914 921 reduced reduce VBD 922 936 LPS-stimulated lps-stimulated JJ 937 939 TF TF NNP 940 944 mRNA mrna NN 945 957 accumulation accumulation NN 957 958 , , , 959 966 thereby thereby RB 967 977 suggesting suggest VBG 978 979 a a DT 980 999 posttranscriptional posttranscriptional JJ 1000 1009 mechanism mechanism NN 1010 1013 for for IN 1014 1017 the the DT 1018 1024 effect effect NN 1024 1025 . . . 1026 1044 Immunofluorescence Immunofluorescence NNP 1045 1052 studies study NNS 1053 1055 of of IN 1056 1061 human human JJ 1062 1071 monocytes monocyte NNS 1072 1077 using use VBG 1078 1088 polyclonal polyclonal JJ 1089 1096 anti-TF anti-tf JJ 1097 1105 antibody antibody NN 1106 1112 showed show VBD 1113 1117 that that IN 1118 1135 N-acetyl-cysteine N-acetyl-cysteine NNP 1136 1145 treatment treatment NN 1146 1155 prevented prevent VBD 1156 1159 the the DT 1160 1174 characteristic characteristic JJ 1175 1187 plasmalemmal plasmalemmal JJ 1188 1200 localization localization NN 1201 1203 of of IN 1204 1206 TF TF NNP 1207 1214 antigen antigen NN 1215 1219 that that WDT 1220 1226 occurs occur VBZ 1227 1229 in in IN 1230 1238 response response NN 1239 1241 to to TO 1242 1245 LPS LPS NNP 1245 1246 . . . 1247 1254 Western western NN 1255 1259 blot blot NN 1260 1268 analysis analysis NN 1269 1275 showed show VBD 1276 1280 that that IN 1281 1298 N-acetyl-cysteine N-acetyl-cysteine NNP 1299 1306 reduced reduce VBD 1307 1310 the the DT 1311 1323 accumulation accumulation NN 1324 1326 of of IN 1327 1330 the the DT 1331 1336 47-kD 47-kd JJ 1337 1343 mature mature JJ 1344 1356 glycoprotein glycoprotein NN 1357 1359 in in IN 1360 1371 LPS-treated lps-treated JJ 1372 1377 cells cell NNS 1377 1378 , , , 1379 1380 a a DT 1381 1388 finding finding NN 1389 1399 consistent consistent JJ 1400 1404 with with IN 1405 1408 the the DT 1409 1416 results result NNS 1417 1419 of of IN 1420 1423 the the DT 1424 1442 immunofluorescence immunofluorescence NN 1443 1450 studies study NNS 1450 1451 . . . 1452 1463 Furthermore furthermore RB 1463 1464 , , , 1465 1470 these these DT 1471 1481 conditions condition NNS 1482 1485 did do VBD 1486 1489 not not RB 1490 1496 result result VB 1497 1499 in in IN 1500 1502 an an DT 1503 1515 accumulation accumulation NN 1516 1518 of of IN 1519 1522 the the DT 1523 1527 less less RBR 1528 1534 mature mature JJ 1535 1540 forms form NNS 1541 1543 of of IN 1544 1546 TF TF NNP 1546 1547 . . . 1548 1552 When when WRB 1553 1563 considered consider VBN 1564 1572 together together RB 1572 1573 , , , 1574 1579 these these DT 1580 1584 data datum NNS 1585 1592 suggest suggest VBP 1593 1597 that that IN 1598 1610 antioxidants antioxidant NNS 1611 1616 exert exert VBP 1617 1622 their their PRP$ 1623 1630 effects effect NNS 1631 1633 by by IN 1634 1643 impairing impair VBG 1644 1655 translation translation NN 1656 1662 and/or and/or CC 1663 1665 by by IN 1666 1673 causing cause VBG 1674 1685 degradation degradation NN 1686 1688 of of IN 1689 1694 newly newly RB 1695 1705 translated translate VBN 1706 1713 protein protein NN 1713 1714 . . . 1715 1718 The the DT 1719 1725 effect effect NN 1726 1728 of of IN 1729 1741 antioxidants antioxidant NNS 1742 1744 on on IN 1745 1750 tumor tumor NN 1751 1759 necrosis necrosis NN 1760 1766 factor factor NN 1767 1775 appeared appear VBD 1776 1778 to to TO 1779 1781 be be VB 1782 1789 species specie NNS 1790 1798 specific specific JJ 1798 1799 , , , 1800 1804 with with IN 1805 1807 no no DT 1808 1814 effect effect NN 1815 1817 on on IN 1818 1829 LPS-induced lps-induced JJ 1830 1835 tumor tumor NN 1836 1844 necrosis necrosis NN 1845 1851 factor factor NN 1852 1854 in in IN 1855 1861 murine murine JJ 1862 1867 cells cell NNS 1867 1868 , , , 1869 1872 but but CC 1873 1877 with with IN 1878 1888 inhibition inhibition NN 1889 1891 in in IN 1892 1897 human human JJ 1898 1907 monocytes monocyte NNS 1907 1908 . . . 1909 1912 The the DT 1913 1932 posttranscriptional posttranscriptional JJ 1933 1939 effect effect NN 1940 1942 of of IN 1943 1955 antioxidants antioxidant NNS 1956 1958 on on IN 1959 1961 TF TF NNP 1962 1972 expression expression NN 1973 1977 data datum NNS 1978 1986 suggests suggest VBZ 1987 1988 a a DT 1989 1994 novel novel JJ 1995 2004 mechanism mechanism NN 2005 2012 whereby whereby WRB 2013 2018 these these DT 2019 2025 agents agent NNS 2026 2031 might might MD 2032 2040 modulate modulate VB 2041 2060 monocyte/macrophage monocyte/macrophage NN 2061 2071 activation activation NN 2071 2072 . . .